Floatz logo

gi-6301

Colon Neoplasms

ImmunityBio, Inc.vaccinePhase 1/2Dormant
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
23/ 100
Competitive Position
95/ 100

Competitive context

840 Active assets in the Colon Neoplasms cohort.

Asset / SponsorPhaseRating
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
MARBLE DUST
James Varani
Phase 2/3BB
FLUOROURACILUM
Washington University School of Medicine
Phase 4BB
PANITUMUMAB
M.D. Anderson Cancer Center
Phase 3BB
Cetuximab
Shanghai Henlius Biotech
Phase 4BB

View all 50 →

Same molecule, other indications

gi-6301 is also rated in:

triple-negative breast carcinomaDormant
C
Indicative ·
38 / 100
View asset →
non-small cell lung carcinomaDormant
C
Indicative ·
38 / 100
View asset →
malignant pancreatic neoplasmDormant
C
Indicative ·
34 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →